Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Accumulated Expenses (2017 - 2025)

Tvardi Therapeutics' Accumulated Expenses history spans 12 years, with the latest figure at $1.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 13.57% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 13.57% increase, with the full-year FY2025 number at $1.3 million, up 13.57% from a year prior.
  • Accumulated Expenses hit $1.3 million in Q4 2025 for Tvardi Therapeutics, up from $1.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TVRD hit a ceiling of $6.5 million in Q4 2023 and a floor of $606000.0 in Q1 2025.
  • Historically, Accumulated Expenses has averaged $2.9 million across 5 years, with a median of $2.7 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: soared 43.58% in 2021 and later tumbled 82.48% in 2024.
  • Tracing TVRD's Accumulated Expenses over 5 years: stood at $5.0 million in 2021, then grew by 5.24% to $5.2 million in 2022, then rose by 24.91% to $6.5 million in 2023, then tumbled by 82.48% to $1.1 million in 2024, then increased by 13.57% to $1.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for TVRD at $1.3 million in Q4 2025, $1.0 million in Q3 2025, and $740000.0 in Q2 2025.